跳至主要内容
临床试验/RBR-83xh37
RBR-83xh37招募中3 期

Ziclague® (Alpinia zerumbet) in patients with hereditary spastic paraplegia: randomized, double-blind, placebo-controlled and crossover clinical trial

niversidade Estadual de Campinas (UNICAMP)0 个研究点开始时间: 2018年8月28日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 80Y(—)

入选标准

  • Age between 18 and 80 years old. Clinical diagnosis of Hereditary Spastic Paraplegia. Ability to walk out of home. Assistive devices are permitted

排除标准

  • Wheelchair bound patients. Additional neurological symptoms that may significantly impact gait such as ataxia, lower motor neuron disease, polyneuropathy, mental retardation or dementia. Fixed tendon contractures. Current botulinum toxin injection or in the last six months. Pregnants or breastfeeding. Refusal to consent form. Skin infection or inflammation at site of interest.

研究者

发起方
niversidade Estadual de Campinas (UNICAMP)

相似试验